化疗相关性腹泻的发生机制和治疗策略

摘要/Abstract

摘要： 化疗相关性腹泻(chemotherapy-induced diarrhea, CID)是肿瘤患者化疗中常见的并发症, 不仅会降低患者的体质和生活质量, 严重者导致化疗被迫中断, 从而影响疗效。许多化疗药物都可以引起腹泻, 其中以氟尿嘧啶类(fluorouracil)和伊立替康(irinotecan, CPT-11)的腹泻发生率最高。本文通过对相关化疗药物(主要是5-FU 和CPT-11)引起CID 的发生机制和治疗策略进行综述, 探讨临床有效防治CID 的措施。

关键词: 化疗相关性腹泻, 伊立替康, 5-FU, 机制, 治疗策略

Abstract: Chemotherapy induced diarrhea(CID) is one of the most common side effects of chemotherapy, it could not only impair the body constitution and life quality of patients, but also result in chemotherapy interruption and less efficacy.Many chemotherapeutic drugs could induce diarrhea, especially fluorouracil and irinotecan have the highest incidence rates.The article reviews the mechanisms and therapeutic strategies of CID as well as explores the effective clinical treatments for cancer patients suffered with CID.

Key words: chemotherapy induced diarrhea, irinotecan, 5-FU, mechanism, therapeutic strategy

中图分类号:

R969

方青芳. 化疗相关性腹泻的发生机制和治疗策略[J]. 中国临床药理学与治疗学, 2009, 14(3): 351-355.

FANG Qing-fang. Mechanisms and therapeutic strategies of chemotherapy induced diarrhea[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 351-355.

参考文献

[1] Gibson RJ, Keefe DM.Cancer chemotherapy-induced diarrhoea and constipation:mechanisms of damage and p revention strategies[J].Support Care Cancer, 2006, 14 (9):890-900.
[2] Richardson G, Dobish R, Pharm B.Chemotherapy induced diarrhea[J].J Oncol Pharm Practice, 2007, 13 (4):181-198.
[3] Sharma R, Tobin P, Clarke SJ.Management of chemotherapy-induced nausea vomiting, oral mucositis and diarrhea[J].Lancet Oncol, 2005, 6(2):93-102.
[4] Kornblau S, Benson AB, Catalano R, et al.Management of cancer treatment-related diarrhea:Issues and therapeutic strategies[J].J Pain Symptom Manage, 2000, 19(2): 118-129.
[5] Saltz LB.Managing chemotherapy-induced diarrhea[J]. Clin Adv Hematol Oncol, 2006, 4(3):203-204.
[6] Arnold RJG, Gabrail N, Raut M, et al.Clinical implications of chemotherapy-induced diarrhea[J].J Support Oncol, 2005, 3(3):227-232.
[7] National Cancer Institute.Common Terminology Criteria for Adverse Effects (CTCAE)v3.0[S].2004.
[8] Viele CS.Overview of chemotherapy induced diarrhea [J].Semin Oncol Nurs, 2003, 19(4):2-5.
[9] Wisinski K, Benson A.Chemotherapy-induced mucositis: focusing on diarrhea[J].J Support Oncol, 2007, 5(6): 270-271.
[10] Arbuckle RB, Huber SL, Zacker C.The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study[J].Oncologist, 2000, 5(3): 250-259.
[11] Shirota Y, Ichikawa W, Uetake H, et al.Intratumoral dihydropyrimidine dehydrogenase messenger RNA level re-flects tumor progression in human colorectal cancer[J]. Ann Surg Oncol, 2002, 9(6):599-603.
[12] Saif MW, Syrigos K, Mehra R, et al.Dihydropyrimidine dehydrogenase deficiency (DPD)in GI malignancies:experience of 4-years[J].Pak J Med Sci Q, 2007, 23(6): 832-839.
[13] Grau JJ, Caballero M, Monzó M, et al.Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropy rimidine adjuvant chemotherapy [J].J Surg Oncol, 2008, 98(2):130-134.
[14] Meta-Analysis Group in Cancer.Toxicity of fluorouracil in patients with advanced colorectal cancer:effect of administration schedule and prognostic factors[J].J Clin Oncol, 1998, 16(11):3537-3541.
[15] Yamada T, Tanaka N, Yokoi K, et al.Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer[J].J Nippon Med Sch, 2008, 75(1):23-27.
[16] Rivory LP, Bowles MR, Robert J, et al.Conversion of irinotecan (CPT-11)to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase[J].Biochem Pharmacol, 1996, 52(7):1103-1111.
[17] Takasuna K, Hagiwara T, Hirohashi M, et al.Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats[J].Cancer Chemother Pharmacol, 1998, 42(4):280-286.
[18] Biason P, Masier S, Toffoli G.UGT1A1＊ 28 and other UGT1A polymorphisms as determinants of irinotecan toxicity[J].J Chemother, 2008, 20(2):158-165.
[19] Tanaka F, Fukuse T, Wada H, et al.The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pharm Biotechnol, 2000, 1 (2):137-164.
[20] Malet-Martino M, Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1):a review[J].Oncologist, 2002, 7(4):288-323.
[21] Terashima M, Fujiwara H, Takagane A, et al.Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J].Gastric Cancer, 2003, 6(Suppl 1):71-81.
[22] Shirasaka T, Shimamato Y, Ohshimo H, et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1)directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators [J].Anticancer Drugs, 1996, 7(5):548-557.